INTRODUCTION
Ever since its discovery in rabbits, leukocytic pyrogen (LP)l has been considered to be the mediator of fever This work was presented in part at the Annual Meeting of The American Society for Clinical Investigation, Atlantic City, N. J., May, 1976. Received for publication 8 September 1976 and in revised form 14 April 1977. 1 Abbreviations used in this paper: LP, leukocytic pyrogen; PBS, phosphate-buffered saline. in all species (1) . However, this substance has proven to be highly labile and difficult to purify from the large quantity and variety of proteins present in crude supernates from stimulated leukocytes (2, 3' . Understandably, to define its role in the pathogenesis of fever, purification of this molecule is a necessity. This is particularly the case with human LP in that LP has yet to be definitively demonstrated in sera from patients with febrile diseases (4, 5) . Even the rabbit, which responds to human LP, has failed to be useful in detecting LP in human febrile plasma (6) . Clearly, a biological assay of human LP is not practical. Thus, techniques such as immunoassays should provide a sensitive method for measuring this substance.
In this paper, we report the first successful method for developing antibodies to human LP in the rabbit. Besides being a prerequisite for an immunoassay, this antibody has provided evidence that this molecule has antigenic identity despite its widespread biological cross-reactivity in rabbits, monkeys, and mice (7) (8) (9) . In addition, this antibody is highly useful in the purification of human LP.
37°C for 30 min, centrifuged at 250 g for 10 min, and resuspended in fresh Hank's balanced salt solution without serum or bacteria at a concentration of 5 million leukocytes per ml. After 18 h at 37°C in a stationary incubator, the suspensions were centrifuged at 2,200 g for 30 min and stored at 4°C in 0.02% sodium azide.
Pyrogen assay. New Zealand albino rabbits weighing 2-3 kg were used in all pyrogen assays. Specific information about training and temperature recording has been reported previously (12) . After intravenous injection into a lateral ear vein, a peak rise of 0.6-1.0"C above base line was considered a single rabbit pyrogenic dose of human LP. To determine this, a two-point dose response was carried out on each preparation of LP using six rabbits (injections were given in triplicate).
Immunization Gel filtration. Preparations of human LP made from the mononuclear layers of Ficoll-Hypaque gradients were concentrated and chromatographed over Sephadex C-50 (fine) in a 165 x 5.6-cm column (Pharmacia Fine Chemicals). This procedure separated the two molecular species of LP (10) . In addition, a Sephadex G-75 (fine) 60 x 2.6-cm column was used for molecular weight determinations. A similar column containing Sephadex G-200 was used to separate immunoglobulins.
Protein determinations. The Lowry method (13) or absorbance at 280 nm was employed to estimate protein content. In both cases, crystallized bovine serum albumin was used as a standard.
Immunoadsorbants. Antiserum was precipitated at 50% (NH4)2SO4 saturation (14) and dialyzed against PBS. This globulin fraction was then coupled to Sepharose 4B (Pharmacia Fine Chemicals) (15, 16 (17) . Gels were subjected to 1.5-2 mA for 2-3 h, removed, and stained in 0.2% Coomassie Blue. Gels were destained in a diffusion destainer (Bio-Rad Laboratories, Richmond, Calif.) and scanned with an automatic recording device at 525 nm (Helena Laboratories, Beaumont, Tex.).
RESULTS
Early bleedings. Despite the formation of precipitates when antiserum and crude pyrogen were mixed, there was no loss of pyrogenic activity with antiserum obtained during the first 5 mo after primary immunization. Immunodiffusion confirmed the presence of precipitating antibody to a variety of human serum proteins. By using pooled antisera from these early bleedings, a globulin fraction was made with (NH4)2SO4 and coupled to Sepharose. Crude human LP, which was concentrated by evaporation and dialyzed against PBS, was applied to this immunoadsorbant. As shown in Fig. 1 , the pyrogenic activity was recovered in the early, nonadhering protein peak. Recovery of pyrogenic activity was nearly 100%. No pyrogen was detected in citric acid-eluted fractions. A similar elution pattern of pyrogen activity was observed when either the 15,000-or 38,000-mol wt pyrogen isolated by gel filtration was passed through this column.
Late bleedings. Neutralizing ability of the rabbit antiserum to crude human LP was observed first in serum obtained 7 mo after primary immunization. The amount of antiserum required to neutralize one dose of human pyrogen fell from 1 ml obtained at 7 mo to 0.003 ml obtained 13 mo after the primary immunization (Fig. 2) . The final concentration of antiserum in each reaction mixture had no effect on its ability to neutralize the pyrogen. Crude human LP in volumes as large as 6 ml/pyrogenic dose or as small as 0.5 ml/pyrogenic dose was neutralized by 10-2 or 10-3 FIGURE 1 50 pyrogenic doses of crude human LP were applied to a rabbit antiserum immunoadsorbant column (3 x 15 cm). Source of globulin was pooled early bleedings (3-6 mo after primary immunization). Rabbits were injected in duplicate, and each point (0) represents mean change in temperature. Each fraction is 10 ml. pH is indicated as a solid line. Protein (0) was measured at 280 nm. Acid elution with citrate buffer, pH 2.5.
ml of antiserum. Similarly, the purity of the pyrogen had no effect in that neutralization occurred when pyrogen preparations of high specific activity (up to 10 ,g protein per pyrogenic dose) were used. Also, neutralization was observed with either the 15,000-or 38,000-mol wt pyrogen which had been prepared from human mononuclear cells and subsequently isolated by gel filtration (10) . In addition, inasmuch as eosinophils have been shown to be a source of human LP (18), a preparation of crude human LP was also made from a buffy coat containing 72% eosinophils, 10% neutrophils, and 18% lymphocytes. This LP was also neutralized by antiserum obtained after 7 mo of immunization (cf. Table II) . Characteristics of the antiserum. Antiserum of proven neutralizing ability against human LP was precipitated at 50% (NH4)2SO4 saturation. All neutralizing activity was recovered in this globulin fraction. The (NH4)2SO4-precipitated protein was then chromatographed over Sephadex G-200, and the protein peaks corresponding to IgM and IgG were isolated and pooled separately. Although significant neutralizing activity against human LP was found in the IgM peak, most of the neutralizing capacity was in the IgG peak. In addition, goat anti-rabbit IgG (ICN Pharmaceuticals Inc., Life Sciences Group, Cleveland, Ohio) was coupled to activated Sepharose 4B. When antiserum containing pyrogen-neutralizing ability was passed over this immunoadsorbant material, no neutralizing activity was found in the unbound protein which passed through the column. All the pyrogen neutralizing activity was in the fraction which had bound to this anti-rabbit IgG and was later eluted with citric acid. These results are summarized in Table I (Table II) .
Attachment of anti-human LP to Sepharose. By using (NH4)2SO4 precipitation, the globulin fraction from the late bleedings (9-12 mo after primary immunization) was coupled to activated Sepharose 4B. Crude human LP was concentrated and placed on this immunoadsorbant. Fig. 3 Rabbits were used as recipients for human, rabbit, and guinea pig LP; monkeys (Macaca mulatta) were used to assay monkey pyrogen (8).
doses) was recovered in four fractions at pH 3.5-2.5. Thus, using the globulin fraction from late bleedings, LP adhered to this immunoadsorbant and was eluted with the acid wash.
Either 15,000-or 38,000-mol wt human LP (obtained from Sephadex G-50 gel filtration of crude LP from human mononuclear cells) was applied to this antihuman LP column. In separate experiments, both molecular species of LP bound to the immunoadsorbant and eluted in the acid wash. In addition, after recovery from the immunoadsorbant, both the 15,000-and 38,000-mol wt pyrogens were individually rechromatographed over Sephadex G-75 with no observed change in their respective elution pattern or molecular weight.
Rabbit and guinea pig macrophage LP were applied to this anti-human LP column, and all pyrogenic activity was recovered in the nonadhering protein peak. These results support the specificity of the neutralization experiments in which anti-human LP antiserum was unable to inactivate these animal pyrogens (Table II) .
Absorption of undesired antibodies from antihuman LP antiserum. In using immunodiffusion and immunoelectrophoresis, we observed that the rabbit anti-human LP antiserum contained large quantities Fig. 3 was applied to this absorbed, anti-human LP immunoadsorbant column. As shown in Fig. 4 , the nonadhering protein peak is significantly larger in comparison to that from the nonabsorbed immunoabsorbant (Fig. 3) , and once again, the pyrogen eluted in a single peak during acid wash. Because of dilutional effects, the protein readings during the citric acid elution of pyrogen are too low for significant comparisons. In addition, in separate experiments, the 15,000-and 38,000-mol wt pyrogens eluted at pH similar to that for crude LP.
Use of immunoadsorbants in purification of human LP. A source of human LP was divided into three equal aliquots. Aliquot A was assayed in rabbits, and the specific activity (micrograms protein per pyrogenic dose) was determined by using the Lowry technique (13). Aliquot B was passed over an unabsorbed, antihuman LP-immunoadsorbant column; the eluted pyrogen peak was concentrated, and the specific activity was determined. Aliquot C was passed over an absorbed, anti-human LP-immunoadsorbant column; the eluted pyrogen peak was similarly concentrated, and the specific activity was determined. Approximately 100 ,ug from each aliquot was then subjected to electrophoresis in sodium dodecyl sulphate gels (see Methods), stained with Coomassie Blue, destained, and the optical density and distribution of the bands were recorded on a scanning device. As depicted in Fig. 5 , three different protein patterns were observed. Crude pyrogen (tracing A) contains numerous high molecular weight proteins present in serum (left side of gel), and the large peak occuring in the middle of the gel was identified as albumin by immunodiffusion. Human LP, eluted from an unabsorbed anti-human LP-immunoadsorbant column (tracing B), contains less large molecular weight serum proteins but increased quantities of albumin and smaller molecular weight proteins (right side of gel). (15) .
Crude LP in these experiments was the product of neutrophils, monocytes, and eosinophils, since lymphocytes do not produce LP (20) . Although monocytes produce a 38,000-mol wt LP in addition to the 15,000-mol wt LP, the larger pyrogen comprises <5% of crude LP after gel filtration (10) . Because of its low isoelectric focusing point (pH 5.1), it is likely that the larger LP has an amino acid composition and antigenic specificity different from that of the 15,000-mol wt pyrogen which has an isoelectric focusing point at pH 6.9. Because antiserum was successful in neutralizing or binding both pyrogens, it may indicate that two specific antibodies are present in the antiserum. Nevertheless, the appearance of neutralizing antibody to both molecules at the same time, despite the low concentration of the 38,000-mol wt LP in the immunizations, does not support the development of two specific antibodies. It is more likely that an antibody is present which is directed against a common antigenic site on both pyrogens. This latter explanation is more feasible because both pyrogens may share the same antigenic site for biologic activity.
It was demonstrated in these studies that anti-LP has a high affinity for human LP. As little as 0.003 ml of antiserum neutralized a single dose of both molecular sizes of LP in crude or partially purified states even when volumes were as large as 6 ml. In addition, when coupled to Sepharose, the antibody bound either the 15,000-or 38,000-mol wt LP until it was dissociated and eluted at low pH. The affinity of this antibody for human LP is sufficient for biological neutralization to take place in the fluid phase, but when attached to immunoadsorbants, this antibody does not alter biological activity. Thus, solid-phase immunoadsorbants can now be applied as a purification method of LP and, as demonstrated in this paper, provide a more efficient means of purification than previously shown for gel filtration, ion exchange, and other techniques (3) .
The use of inhibitors of mRNA and protein synthesis has provided indirect evidence that human LP is a newly synthesized protein (19) . This conclusion is based on the ability of these inhibitors to prevent formation of biologically active LP. The present studies also reveal that cycloheximide prevents the synthesis of antigenic portions of the LP molecule, because we were unable to absorb anti-LP with leukocyte supernates made in the presence of cycloheximide. In addition, these absorption experiments support the fact that anti-LP antibody is directed against LP and not another protein to which LP may bind. For example, noncovalent binding of small molecules, such as LP, to large serum molecules, such as albumin, could have occured in the immunizing material. Under these conditions, antibody to LP may reflect antibody to such a large protein; however, the presence of serum proteins in leukocyte supernates prepared with cycloheximide had no effect on the titer of anti-LP during the absorption experiments. Therefore, it is unlikely that anti-LP is directed against a large protein which binds LP.
In summary, specific antibody to human LP has established antigenic identity for this potent biological molecule and that both 15,000-and 38,000-mol wt components may share a common antigenic site (or sites). This antibody also provides us with an efficient method of purifying LP from crude leukocyte supernates. Production of antibody is the first and most essential step in the development of an immunoassay for this molecule, a technique which seems to be necessary if we are to measure LP in patients. Finally, this antibody may provide a means to sttudy the origin, receptors, and metabolic disposition of LP and its role in the pathogenesis of fever.
